Rimegepant

Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the preventative treatment of episodic migraine in adults.[1][3] It is taken by mouth to dissolve on or under the tongue.[1] It works by blocking CGRP receptors.[4]

Rimegepant
Clinical data
Trade namesNurtec ODT, Vydura
Other namesBHV-3000, BMS-927711
AHFS/Drugs.comMonograph
MedlinePlusa620031
License data
Routes of
administration		By mouth
Drug classCalcitonin gene-related peptide receptor antagonist
ATC code
Legal status
Legal status
  • US: ℞-only [1]
  • EU: Rx-only [2]
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • [(5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H28F2N6O3
Molar mass534.568 g·mol−1
3D model (JSmol)
SMILES
  • N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F
InChI
  • InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1
  • Key:KRNAOFGYEFKHPB-ANJVHQHFSA-N

In the United States, rimegepant was approved for treating acute migraine in February 2020,[5] and its approval was extended to preventing episodic migraine in June 2021.[1] It is produced and marketed by Pfizer.[6] In March 2021, rimegepant was approved for medical use in the United Arab Emirates and in Israel.[7][8][9]

Medical uses

Rimegepant is indicated for the treatment of acute migraine with or without aura in adults and for the preventative treatment of episodic migraine in adults.[1][3][2]

Mechanism of action

Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.[4]

History

Rimegepant was developed by Biohaven Pharmaceuticals, which markets the drug in the United States after receiving FDA approval in February 2020.[5][10] Approval was based on evidence from one clinical trial of 1,351 subjects with migraine headaches.[3]

Society and culture

On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vydura, intended for the prophylaxis and acute treatment of migraine.[11] The applicant for this medicinal product is Biohaven Pharmaceutical Ireland DAC.[11] Rimegepant was approved for medical use in the European Union in April 2022.[2]

References
  1. "Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Archived from the original on 28 November 2020. Retrieved 19 March 2020.
  2. "Vydura EPAR". European Medicines Agency (EMA). 22 February 2022. Archived from the original on 16 October 2022. Retrieved 11 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. "Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Archived from the original on 1 October 2020. Retrieved 19 March 2020. This article incorporates text from this source, which is in the public domain.
  4. Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet. Neurology. 14 (10): 1010–22. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968. S2CID 26523013.
  5. "Drug Approval Package: Nurtec ODT". U.S. Food and Drug Administration (FDA). 26 March 2020. Archived from the original on 27 December 2021. Retrieved 16 October 2022.
  6. "Pfizer Completes Acquisition of Biohaven Pharmaceuticals". Pfizer (Press release). 3 October 2022. Archived from the original on 5 October 2022. Retrieved 16 October 2022.
  7. "Biohaven Pharma's Nurtec ODT Approved In Israel For Acute Treatment Of Migraine". StreetInsider.com. Archived from the original on 3 June 2021. Retrieved 3 June 2021.
  8. "Nurtec ODT: Treatment and Prevention of Migraine? And How to Get It". Migraine Again. 14 April 2021. Archived from the original on 3 June 2021. Retrieved 3 June 2021.
  9. "Biohaven's Nurtec ODT Approved In United Arab Emirates For Acute Treatment Of Migraine". Biohaven Pharmaceuticals (Press release). Archived from the original on 11 March 2021. Retrieved 3 June 2021.
  10. "Biohaven's Nurtec ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults" (Press release). Biohaven Pharmaceuticals Holding Company Ltd. 27 February 2020. Archived from the original on 26 July 2021. Retrieved 28 February 2020 – via PR Newswire.
  11. "Vydura: Pending EC decision". European Medicines Agency (EMA). 24 February 2022. Archived from the original on 27 February 2022. Retrieved 27 February 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.